1. Yan Li#, Ya Chu#, Guangjiang Shi#, Xiaobin Wang, Wanli Ye, Chun Shan, Dajia Wang, Di Zhang, Wei He, Jingwei Jiang, Yuhong Han, Shuqian Ma, Zhen Chen, Zhiyu Li, Yong Yang, Chen Wang*, Xi Xu*, Hongxi Wu*. A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. Acta Pharmaceutica Sinica B, 2022. May.10.DOI:10.1016/j.apsb.2022.05.003 (中科院一区;IF=14.903).
2. Hongxi Wu#, Yan Li#, Guangjiang Shi#, Shijia Du#, Xiaobin Wang, Wanli Ye, Zixuan Zhang, Ya Chu, Shuqian Ma, Dajia Wang, Yuan Li, Zhen Chen, Lutz Birnbaumer, Zhuo Wang*, Yong Yang*. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology.2022 Jan 6. DOI: 10.1002/hep.32316. (中科院一区;IF=17.298).
3. Hongxi Wu#, Linjun You#, Yan Li#, Zhili Zhao#, Guangjiang Shi, Zhen Chen, Zhuo Wang, Xianjing Li, Shijia Du, Wanli Ye, Xiaofang Gao, Jingjing Duan,Yan Cheng, Weiyan Tao, Jinsong Bian, Jin-Rong Zhou, Qingyi Zhu*,Yong Yang*. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Research. 202080(13): 2459. (IF: 12.701).
4. Guang-Jiang Shi#, Yan Li#, Qiu-Hua Cao, Hong-Xi Wu, Xin-Ying Tang, Xing-Hua Gao,Jian-Qiang Yu, Zhen Chen, Yong Yang. In vitro and in vivo evidence that quercetin protects against diabetes and its complications: A systematic review of the literature. Biomedicine &Pharmacotherapy. 109 (2019) 1085–1099. (中科院二区,IF=6.53).